EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Ensysce Biosciences, Inc. (ENSC) had EBIT Margin of -127.64% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$1.37M |
|
$-1.73M |
|
-- |
|
$1.37M |
|
$3.12M |
|
$-1.75M |
|
$0.02M |
|
$-1.73M |
|
$-1.73M |
|
$-1.73M |
|
$-1.73M |
|
$-1.73M |
|
$-1.73M |
|
$-1.75M |
|
$-1.75M |
|
2.20M |
|
2.20M |
|
$-0.79 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$5.28M |
|
-- |
|
$0.29M |
|
$5.57M |
|
$2.51M |
|
-- |
|
$0.00M |
|
$2.51M |
|
$3.06M |
|
$3.06M |
|
$3.06M |
|
2.39M |
|
| Cash Flow Statement Financials | |
$-4.41M |
|
-- |
|
$3.12M |
|
$3.50M |
|
$2.21M |
|
$-1.29M |
|
$0.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.10 |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
100.00% |
|
-127.64% |
|
|
EBIT Margin |
-127.64% |
-- |
|
-126.40% |
|
-126.39% |
|
$-4.41M |
|
-- |
|
-- |
|
-- |
|
0.25 |
|
-- |
|
1.14 |
|
79.08 |
|
-56.64% |
|
-56.64% |
|
-31.10% |
|
-56.64% |
|
$1.28 |
|
$-2.00 |
|
$-2.00 |
|